| Literature DB >> 22436128 |
Giovanni Leonardi1, Marie Vahter, Felicity Clemens, Walter Goessler, Eugen Gurzau, Kari Hemminki, Rupert Hough, Kvetoslava Koppova, Rajiv Kumar, Peter Rudnai, Simona Surdu, Tony Fletcher.
Abstract
BACKGROUND: Inorganic arsenic (iAs) is a potent carcinogen, but there is a lack of information about cancer risk for concentrations < 100 μg/L in drinking water.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22436128 PMCID: PMC3346769 DOI: 10.1289/ehp.1103534
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Study population and characteristics [n (%)].
| Characteristic | Cases | Controls | Total (n) | |||
|---|---|---|---|---|---|---|
| Country/county | ||||||
| Hungary, total | 160 (30.3) | 249 (46.1) | 409 | |||
| Bács-Kiskun | 90 (17.1) | 101 (18.7) | 191 | |||
| Békés | 23 (4.4) | 23 (4.3) | 46 | |||
| Csongrád | 24 (4.5) | 61 (11.3) | 85 | |||
| Jász-Nagykun-Szolnok | 23 (4.4) | 64 (11.9) | 87 | |||
| Romania, total | 158 (29.9) | 156 (28.9) | 314 | |||
| Arad | 90 (17.0) | 100 (18.5) | 190 | |||
| Bihor | 68 (12.9) | 56 (10.4) | 124 | |||
| Slovakia, total | 211 (39.9) | 135 (25.0) | 346 | |||
| Banska Bystrica | 92 (17.4) | 70 (13.0) | 162 | |||
| Nitra | 119 (22.5) | 65 (12.0) | 184 | |||
| Age (years) | ||||||
| < 45 | 20 (3.9) | 55 (10.3) | 75 | |||
| 45–49 | 33 (6.4) | 47 (8.8) | 80 | |||
| 50–54 | 31 (6.0) | 61 (11.4) | 92 | |||
| 55–59 | 63 (12.1) | 77 (14.5) | 140 | |||
| 60–64 | 65 (12.5) | 76 (14.3) | 141 | |||
| 65–69 | 106 (20.4) | 83 (15.6) | 189 | |||
| 70–74 | 113 (21.7) | 78 (14.7) | 191 | |||
| 75–79 | 89 (17.1) | 56 (10.5) | 145 | |||
| Missing | 9 | 7 | 16 | |||
| Sex | ||||||
| Male | 237 (44.8) | 278 (51.5) | 515 | |||
| Female | 292 (55.2) | 262 (48.5) | 554 | |||
| Skin response to 1-hr midday sun | ||||||
| Blistered | 71 (13.7) | 59 (11.1) | 130 | |||
| Sunburned | 114 (22.0) | 83 (15.6) | 197 | |||
| Mild burn | 169 (32.6) | 161 (30.3) | 330 | |||
| Tan | 157 (30.3) | 206 (38.8) | 363 | |||
| No change | 7 (1.4) | 22 (4.1) | 29 | |||
| Missing | 11 | 9 | 20 | |||
| Skin complexion | ||||||
| Light | 271 (51.3) | 222 (41.2) | 493 | |||
| Medium | 241 (45.6) | 258 (47.9) | 499 | |||
| Dark | 16 (3.0) | 59 (11.0) | 75 | |||
| Missing | 1 | 1 | 2 | |||
| Total | 529 (100.0) | 540 (100.0) | 1,069 | |||
| Years of education (mean ± SD) | 10.1 ± 4.1 | 10.2 ± 3.7 | 10.1 ± 3.9 |
Results of logistic regression models of iAs exposure by quintile and BCC in the ASHRAM study population [OR (95% confidence interval)].
| Arsenic exposure index/quintile (range of exposure in controls) | Adjusteda | Additionally adjustedb | Trend test (p-value) | |||
|---|---|---|---|---|---|---|
| Lifetime average iAs concentration (μg/L) | 0.001 | |||||
| 0.00–0.68 | 1.00 | 1.00 | ||||
| 0.68–0.98 | 1.27 (0.82, 1.97) | 1.39 (0.89, 2.19) | ||||
| 0.98–7.00 | 1.02 (0.67, 1.56) | 1.20 (0.77, 1.88) | ||||
| 7.10–19.43 | 1.63 (0.93, 2.85) | 1.73 (0.97, 3.11) | ||||
| 19.54–167.29 | 2.81 (1.62, 4.87) | 3.03 (1.70, 5.41) | ||||
| Peak daily iAs dose rate (μg/day) | 0.001 | |||||
| 0.00–0.73 | 1.00 | 1.00 | ||||
| 0.73–1.48 | 0.93 (0.62, 1.39) | 0.91 (0.59, 1.39) | ||||
| 1.48–9.09 | 1.29 (0.86, 1.95) | 1.55 (1.00, 2.41) | ||||
| 9.09–32.23 | 1.78 (1.05, 3.02) | 1.76 (1.01, 3.07) | ||||
| 32.23–242.14 | 2.31 (1.32, 4.03) | 2.50 (1.39, 4.49) | ||||
| Cumulative iAs dose (g) | 0.001 | |||||
| 0.00–0.01 | 1.00 | 1.00 | ||||
| 0.01–0.03 | 1.02 (0.68, 1.52) | 1.09 (0.72, 1.67) | ||||
| 0.03–0.13 | 1.19 (0.78, 1.81) | 1.46 (0.93, 2.27) | ||||
| 0.13–0.55 | 1.73 (1.02, 2.91) | 1.76 (1.02, 3.04) | ||||
| 0.55–4.46 | 2.45 (1.39, 4.32) | 2.63 (1.45, 4.78) | ||||
| Relative risks of BCC were estimated as ORs comparing risk of cancer in a quantile with the quintile of lowest exposure. Range of iAs exposure within each quintile is expressed in the unit of measure specific for each exposure index. aAdjusted for county, age, and sex, based on n = 1,022 for peak dose rate, n = 1,025 for lifetime average concentration, and n = 1,011 for cumulative dose. bAdditionally adjusted for education, skin response to 1-hr midday sun, and skin complexion, based on n = 989 for peak dose rate, n = 992 for lifetime average concentration, n = 979 for cumulative dose. | ||||||
Logistic regression models of iAs exposure and BCC in the ASHRAM study population [OR (95% confidence interval)].
| Arsenic exposure index | All observations (n = 1,069) | Observations with metabolites ≥ 2.5 μg/L (n = 856) | Observations with metabolites ≥ 2.5 μg/L and lifetime average As < 40.7 μg/L (n = 736) | |||
|---|---|---|---|---|---|---|
| Lifetime average As concentration | 1.18 (1.08, 1.28) | 1.15 (1.06, 1.26) | 1.41 (1.14, 1.76) | |||
| Peak daily As dose rate | 1.13 (1.07, 1.20) | 1.12 (1.06, 1.19) | 1.18 (1.04, 1.33) | |||
| Cumulative As dose | 1.10 (1.01, 1.19) | 1.08 (1.00, 1.18) | 1.16 (0.95, 1.41) | |||
| Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10-μg/L increase in lifetime average iAs concentration, a 10‑μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 50 years of drinking 1.5 L water/day containing 10 μg/L iAs. All models adjusted for county, age, sex, education, skin response to 1-hr midday sun, and skin complexion. | ||||||
Associations between BCC and As according to urine iAs metabolite levels among participants with sum of iAs metabolites ≥ 2.5 μg/L (n = 856).
| Arsenic exposure index | < Mediana [ORb (95% CI)] | ≥ Mediana [ORb (95% CI)] | p-Valuec | |||
|---|---|---|---|---|---|---|
| Lifetime average concentration | ||||||
| DMA% | 1.21 (1.10, 1.35) | 1.03 (0.92, 1.15) | 0.017 | |||
| MA% | 1.04 (0.94, 1.17) | 1.21 (1.09, 1.35) | 0.032 | |||
| Peak daily As dose rate | ||||||
| DMA% | 1.14 (1.06, 1.23) | 1.05 (0.96, 1.15) | 0.098 | |||
| MA% | 1.05 (0.97, 1.15) | 1.15 (1.06, 1.23) | 0.095 | |||
| Cumulative As dose | ||||||
| DMA% | 1.11 (1.01, 1.22) | 0.99 (0.88, 1.12) | 0.119 | |||
| MA% | 1.02 (0.91, 1.14) | 1.10 (1.00, 1.22) | 0.222 | |||
| Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10 μg/L increase in lifetime average iAs concentration, a 10-μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 50 years of drinking 1.5 L water/day containing 10 μg/L iAs. aMedian DMA%, 76.6%; median MA%, 15.8%. bThese ORs are stratum specific because they estimate effect of iAs on cancer as a linear effect, separately by level of metabolite, for both DMA% and MA%, and controlled for potential confounders county, age, sex, education, skin response to 1-hr midday sun, and skin complexion. cp-Values for multiplicative interaction terms between dichotomous variables for DMA% or MA% and continuous variables for iAs exposure indexes (Wald test). | ||||||